Amyotrophic Lateral Sclerosis (ALS) or motor neuron disease in a progressive, fatal neurodegenerative disease, for which there is no treatment. Now, researchers from the University of Melbourne report that a new drug showed positive effects in a clinical trial involving ALS.
The trial assessed the optimal dose of CuATSM, the new drug, and it involved 32 patients. Treated patients showed improved lung function and cognitive ability together with a much slower progression of the disease.
Next, the scientists plan to start a large randomized, placebo-controlled double-blind Phase 2 trial in mid- to late 2019 to test the effectiveness of the treatment on a larger sample of patients.
Read the full story: University of Melbourne
Scientific publication: Collaborative Medical Development Clinical Trials